Perfluorooctane sulfonate (PFOS) is an environmentally persistent chemical. Dietary 100 ppm PFOS fed to male mice and rats for 4 weeks caused hepatic steatosis through an unknown mechanism. Choline deficient diets can cause hepatic steatosis. A hepatic choline:PFOS ion complex was hypothesized to cause this effect in mice. This study tested whether dietary choline supplementation attenuates PFOS-induced hepatic steatosis in rats. Sprague Dawley rats (12/sex/group) were fed control, choline supplemented (CS), 100 ppm PFOS, or 100 ppm PFOS þ CS diets for 3 weeks. Male rats fed both PFOS-containing diets had decreased serum cholesterol and triglycerides (TGs) on days 9, 16, and/or 23 and increased hepatic free fatty acids and TG (ie, steatosis). Female rats fed both PFOS diets had decreased serum cholesterol on days 9 and 16 and decreased hepatic free fatty acid and TG at termination (ie, no steatosis). Liver PFOS concentrations were similar for both sexes. Liver choline concentrations were increased in male rats fed PFOS (6CS), but the increase was lower in the PFOS þ CS group. Female liver choline concentrations were not altered by any diet. These findings demonstrate a clear sexrelated difference in PFOS-induced hepatic steatosis in the rat. Additional evaluated mechanisms (ie, nuclear receptor activation, mRNA upregulation, and choline kinase activity inhibition) did not appear to be involved in the hepatic steatosis. Dietary PFOS (100 ppm) induced hepatic steatosis in male, but not female, rats that was not attenuated by choline supplementation. The mechanism of lipid accumulation and the sex-related differences warrant further investigation.
Perfluorooctane sulfonate (PFOS) is bioaccumulative in rats (Seacat et al., 2003b) , monkeys (Seacat et al., 2002) , and humans (Olsen et al., 2007) and is environmentally persistent (United Nations, 2009) . Dietary exposures of 100 ppm PFOS in mice (Zhang et al., 2016) and rats (Curran et al., 2008) for 4 weeks caused hepatic subcellular vacuolation that may indicate lipid accumulation (ie, hepatic steatosis). These PFOS dietary exposures caused serum concentrations (eg, 400-600 ppm; Zhang et al., 2016) that are considerably higher than occupational serum values in 1999 (12.8 ppm; Olsen et al., 1999) and the general U.S. population serum values in 2010 (0.008 ppm; Olsen et al., 2012b) . However, the mechanism for hepatic steatosis induction in rats following high PFOS dietary exposure has not been established and warrants investigation.
One common method for inducing hepatic steatosis in animal models is the use of methionine-choline deficient diets (George et al., 2003) . Methionine-choline deficient diets reduce the available phosphatidylcholine for very low-density lipoprotein (VLDL) packaging, thus reducing VLDL secretion and increasing hepatic lipid retention by week 2 and progressing to hepatic inflammation by week 5 (George, et al., 2003) . These findings are consistent with the "hepatic cytoplasmic homogeneity", decreased serum cholesterol, and decreased serum triglycerides (TGs) following 100 ppm PFOS dietary exposure for 4 weeks in Sprague Dawley rats (Curran et al., 2008) . Curran et al. (2008) reported "cytoplasmic homogeneity", but did not report hepatocellular vacuolation, which is apparent in the liver of a rat fed 100 ppm PFOS ( Figure 3B of that publication). A recent study (Zhang et al., 2016) showed that male mice fed 100 ppm PFOS in a minimal methionine-choline deficient diet had an exacerbated hepatic steatotic phenotype relative to male mice that were fed the minimal methionine-choline deficient diet alone. In addition, the results of that study supported the hypothesis of the formation of a hepatic choline-PFOS ion complex causing a functional choline deficiency as a putative mechanism that could produce the observed hepatic steatosis in mice.
To further investigate this hypothesis, male and female Sprague Dawley rats were fed basal diet (control), choline supplemented diet (CS), 100 ppm PFOS diet (PFOS), or 100 ppm PFOS with choline supplement (PFOS þ CS) for 3 weeks to investigate the potential for choline supplementation to attenuate the lipid accumulation. The choline supplement concentration was selected based on the results of a 4-week choline Supplementary Material in Sprague Dawley rats (Bagley et al., 2017) . In addition, we investigated: (1) whether key liver mRNA transcripts involved in lipid accumulation (eg, CD36) were upregulated in the PFOS-exposed rats, (2) whether PFOS can activate key nuclear receptors in vitro that promote lipid accumulation (eg, pregnane X receptor [PXR] ), and (3) whether PFOS can directly inhibit choline kinase activity in vitro, because choline kinase converts choline to phosphocholine which is the rate-limiting step in the anabolism of phosphatidylcholine from choline.
MATERIALS AND METHODS
Perfluorooctane sulfonate. The PFOS used in this study was potassium perfluorooctanesulfonate salt (CASRN 2795-39-3, K þ PFOS, lot 217, purity 86.9%) obtained from 3M Company (St. Paul, Minnesota) . A detailed list of the impurities in this lot was presented previously in Seacat et al. (2002) .
Diets. AIN-93G diets were obtained from Dyets, Inc. (Bethlehem, Pennsylvania) containing basal choline (control, 4.2 g choline bitartrate/kg diet, 1700 ppm choline, catalog number d510176, lot 3183-2), CS (diet, 12.5 g choline bitartrate/kg diet, 5125 ppm choline, catalog number d510201, lot 3183-3), basal choline with 100 ppm PFOS (100 ppm PFOS, 4.2 g choline bitartrate/kg with 120 ppm K þ PFOS diet, 1700 ppm choline, catalog number d510179, lot 3183-4), and CS with 100 ppm PFOS (PFOS þ CS, 12.5 g choline bitartrate/kg with 120 ppm K þ PFOS diet, 5125 ppm choline, catalog number d510202, lot 3183-5). The final dietary concentration was 100 ppm PFOS when accounting for the potassium salt and purity. The amount of sucrose used in each applicable diet was reduced to account for the weight-balance of the increased choline bitartrate and/or added PFOS. The caloric content of each diet was 3.9 kcal/g. All diets were stored at approximately 4 C during the study and used prior to the expiration dates per the vendor instructions. Dietary choline concentrations were verified by choline analysis at Covance Laboratories (Madison, Wisconsin) using a method adapted from AOAC Official Method 999.14 (AOAC International, 2005) . Briefly, 6 samples of each diet were obtained from the bottom, middle, and top of each container. The diet samples were hydrolyzed at 70 C and, following pH adjustment to 3.75 6 0.25 with NaOH or HCl as appropriate, treated with phospholipase D followed by choline oxidase to produce peroxide. In the presence of peroxidase, phenol was oxidized, and a chromophore was produced with 4-aminoantipyrine. Absorbance of this chromophore at 505 nm was directly related back to the choline content of the sample. The lower limit of quantitation of this method was 67 ppm choline in the diet. Dietary PFOS concentrations were verified using a previously described LC-MS/MS procedure (Zhao et al., 2015) .
Animal selection and husbandry. This study was performed in a laboratory that is accredited by the International Association for the Accreditation of Laboratory Animal Care. All procedures involving laboratory rats were reviewed and approved by the Institutional Animal Care and Use Committee associated with the facility in which the laboratory rats were housed. Animal care and procedures followed the U.S. Department of Health and Human Services guidelines (ILAR, 2010) and the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985) . The study was performed under the supervision of an attending laboratory veterinarian. Six-to eight-week-old adult Sprague Dawley rats (48/sex) were obtained from Harlan Laboratories (Indianapolis, Indiana) at body weights ranging from 223.9 to 258.0 g (males) and 144.1 to 175.6 g (females). The rats were individually housed in hanging wire cages in a dedicated animal room maintained at a temperature of 72 F 6 3 F, relative humidity of 30%-70%, with a minimum of 10 exchanges of room air per hour and a 12-h light/ dark cycle. Room light intensity was maintained at or below 500 lux during the study. Cages were changed weekly. Large marbles and Nylabone chewables were provided to each rat as enrichment. Tap water was available ad libitum throughout the study. All rats were acclimated to the room conditions and fed an ad libitum basal diet for 7 days prior to randomization and the initiation of the study. Twelve rats/sex were randomly assigned to the basal diet (control), CS diet, 100 ppm PFOS diet (PFOS), and 100 ppm PFOS with choline supplement diet (PFOS þ CS) groups. There were no significant differences in the initial group mean body weights (data not provided). Rats were fed the applicable diet ad libitum for 3 weeks.
Inlife procedures. Clinical observations, body weights, and food intake (accounting for spillage) were measured daily. Blood was collected in untreated Vacutainer tubes (Becton Dickinson and Company, San Jose, California) via the jugular vein of nonfasted rats on days 2, 9, and 16. Rats were fasted overnight prior to necropsy. Fasted body weights were recorded on day 23. All rats were euthanized on day 23 by CO 2 asphyxiation, and blood was collected in untreated Vacutainer tubes by exsanguination via the abdominal aorta. The collected blood was allowed to clot and was centrifuged at 1500 Â g for 15 min at 10 C in an Avanti J-30I centrifuge (Beckman Coulter, Brea, California). The resulting serum was collected, transferred to labeled tubes, and stored at À70 C until analysis for PFOS content, choline content, and clinical chemistry parameters. All euthanized rats were subjected to gross evaluation of all organs. Liver weights were recorded. Liver samples were collected from the right median lobe and left lateral lobe and fixed in neutral-buffered formalin for histopathology. Flash frozen liver samples were collected for: (1) hepatic PFOS concentration analysis; (2) hepatic cholesterol, TG, and free fatty acid (FFA) content; and (3) hepatic mRNA content analysis (collected in RNALater, Applied Biosystems, Foster City, California). The flash frozen liver samples were stored at À70 C until analysis.
Serum and liver choline analysis. Serum choline concentrations were measured using a previously described method (Bagley et al., 2017) . In brief, thawed rat serum samples were prepared at a 1:6 dilution in acetonitrile, 0.1 N formic acid was added, and the solution was centrifuged at 3000 Â g for 10 min. The organic layer was removed and stored at À70 C until analysis.
The liver samples were prepared for choline concentration analysis using a modification of the Holm method (Holm et al., 2003) . The frozen liver samples were prepared at 1:6 in acetonitrile and allowed to thaw for approximately 5 minutes. The samples were homogenized in tubes containing ceramic beads using a Precellys Evolution tissue homogenizer (Bertin Instruments) set for 10 cycles of 20 s each at 8000 rpm with a 30 s pause between cycles. The resulting homogenate was centrifuged at 5800 Â g for 2 minutes, and the supernatant was collected and stored at À70 C until analysis.
The prepared liver or serum samples were run on an acetonitrile gradient using a Sciex API 5000 mass spectrometer (Applied Biosystems/MDS-Sciex Instrument Corporation, Framingham, Massachusetts) with Turbo Ion Spray (pneumatically assisted electrospray ionization) in positive ion mode. Separation was completed on a Phenomenex polar HPLC column (150 Â 3.0 mm, 4 mm, Phenomenex, Torrance, California). The transition ions were monitored at:
Choline: 104 amu transitioned to 60 amu Choline Internal Standard (trimethyl-d9-labeled): 113 amu transitioned to 69 amu The lower limit of quantitation for choline content analysis was 5 ng/ml (ie, 5 ppb). The quadratic regression R 2 for the standard curve in this study was 0.9995.
Serum and liver PFOS concentration analyses. Serum and liver PFOS concentrations were determined using a previously described LC-MS/MS procedure (Chang et al., 2012) .
Clinical chemistry. Clinical chemistry analyses of the collected serum from day 2, 9, 16, and 23 were performed by Marshfield Labs (Marshfield, Wisconsin). All serum was evaluated for glucose, aspartate aminotransferase, alanine transaminase, gamma-glutamyl transferase, alkaline phosphatase, total bilirubin, direct bilirubin, indirect bilirubin, total cholesterol, high--density lipoprotein (HDL), low-density lipoprotein (LDL), TGs, total protein, blood urea nitrogen, creatinine, phosphorus, calcium, sodium, potassium, chloride, bicarbonate, anion gap, creatine kinase, lactate dehydrogenase, amylase, lipase, albumin, globulin, albumin/globulin ratio, urea/creatinine ratio, and sodium/potassium ratio using a Beckman Coulter AU 5800 Clinical Chemistry System.
Histopathology. Histopathology of the liver samples was performed by Charles River Laboratories (Durham, North Carolina). Formalin-fixed liver was embedded in paraffin; 5 mm sections were cut using a microtome and stained with hematoxylin and eosin for histopathology evaluation. The hematoxylin and eosin slides were examined by a board-certified veterinary pathologist using light microscopy. Findings were scored for severity using a 0-4 scale (unremarkable, minimal, mild, moderate, and severe). Frozen samples were prepared from the formalin-fixed liver samples; 5 mm sections were cut using a cryotome and stained with Oil Red O for fat content evaluation. Additional specimens of formalin-fixed liver were placed in 1% osmium tetroxide for 2 h, then subjected to routine histologic processing, sectioning at 5 mm, and light microscopic evaluation for osmium-stained fat content. The Oil Red O-, osmium tetroxide-, and hematoxylin and eosin-stained samples were scanned at 20Â magnification using the NanoZoomer whole slide scanner (Hamamatsu Corporation, Bridgewater, New Jersey). Morphometric analysis was performed using the Visiopharm Integrator System, v. 4.4.4.0 (Visiopharm, Broomfield, Colorado) with 40% of the entire tissue section sampled by systematic uniform random sampling. The morphometric results are presented as the percent of the area sampled that was stained.
Liver total FFAs, cholesterol, and TG analyses. The total FFAs, cholesterol, and TG concentrations in each flash frozen liver sample were analyzed by Charles River Research Animal Diagnostics Services (Wilmington, Massachusetts) using the Wako HR Series NEFA-HR(2) fatty acid ELISA, Wako Total Cholesterol ELISA kit, and the Wako Triglycerides Microtiter Assay kit (Wako Diagnostics, Mountain View, California). The protein content of each flash frozen liver sample was determined by bicinchoninic acid assay (Pierce, BCA Protein Assay Kit, Rockford, Illinois). mRNA analyses. Flash frozen liver samples were selected for mRNA analyses from rats (4/sex/group) that were fed the control and PFOS only diets. To select this subset of rats, the osmium tetroxide lipid content results for each group were stratified into quartiles and one member of each quartile was randomly selected for mRNA analysis to reduce the potential for lipid content bias to influence the mRNA results. The CS and PFOS þ CS groups were not analyzed for mRNA production.
Tissue homogenization, RNA isolation, and reverse transcription PCR were performed using methods previously described (Bjork et al., 2011) . In brief, flash frozen liver samples (0.5 cm long) were added to 1.5 ml of DNase stock solution (RNase-Free DNase Set, Qiagen, Valencia, California) that was diluted 1:8 with the Qiagen proprietary buffer (RLT) that contained 10 ml/ml beta-mercaptoethanol. The tissue was homogenized using an UltraTurrax T25 (IKA Works, Wilmington, North Carolina). The homogenate was centrifuged on a Qiashredder column (Qiagen) for one minute at 9600 Â g and then transferred to an equal volume of 50% ethanol. Then, 650 ml of the solution was transferred to RNeasy mini-columns (Qiagen), centrifuged for 1 min at 8000 Â g, and the mRNA was isolated using the RNEasy Minikit (Qiagen). The resulting RNA was quantified using a NanoDrop ND-1000 (ThermoFischer Scientific, Watham, Massachusetts). Reverse transcription was performed with the Omniscript RT kit (Qiagen), 9 random primers (IDT, Coralville, Iowa) and approximately 1.0 mg RNA per liver sample. The resulting cDNA was stored at À20 C until quantitative PCR was performed. Primers were designed for Rattus norvegicus enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase (Ehhadh), stearoyl-CoA desaturase (Scd1), Rattus norvegicus CD36 molecule (Cd36), cell death-inducing DFFA-like effector c (fat-specific protein, Fsp27), and glutathione S-transferase theta 1, transcript variant X2 (Gsst1) as shown in Supplementary Table 1. These rat genes were selected because the proteins they produce are important for oxidative stress response (GSST1) and lipid synthesis (SCD1), beta-oxidation (EHHADH), and transport (FSP27 and CD36). The primers were designed using the Primer-BLAST interface (NIH, National Center for Biotechnology Information (NCBI)) to produce a product with 250 base pairs; inclusion of at least one intron, when possible; a target melting temperature of 60 C; and less than one degree of difference in melting temperature between the forward and reverse strands. The cDNA from the liver samples was exposed to the primers and quantitative PCR was performed with a Roche LightCycler and Sybr Green Master mix kit (Roche Applied Science, Indianapolis, Indiana). DNA standards were prepared using previously described methods (Bjork and Wallace, 2009 ) and the results for each primer were compared with the results for the 18 s subunit to determine the fold-change for a given mRNA.
In vitro nuclear receptor activation analyses. A luciferase reporter cell assay was performed by Indigo Biosciences (State College, Pennsylvania) using HEK 293 cells transfected with plasmid hybrids for rat constitutive androstane receptor (CAR, NR1I3) or rat PXR (NR1I2) and Chinese hamster ovary cells transfected with plasmid hybrids for human liver X receptor alpha (LXR-alpha, NR1H3), rat liver X receptor beta (LXR-beta, NR1H3), or mouse/rat peroxisome proliferator-activated receptor gamma (PPAR-gamma, NR1C3). All of the plasmids contained a yeast Gal4 N-terminal DNA binding domain and the reporter gene, firefly luciferase, was linked to the Gal4 upstream sequence. Cytotoxicity potential was assessed using the Indigo Biosciences Live Cell Multiplex assay (State College). Cells were treated in triplicate with 0.1% DMSO (vehicle) or 0.4, 1.3, 3.7, 11.1, 33.3, or 100 mM PFOS for a 24-h exposure. Gene-specific reference positive controls were provided by Indigo Biosciences and were used to validate each test. The rat constitutive androstane receptor test was an inverse-agonist test to evaluate the potential for activation and inhibition, while the other reporter assays were performed as agonist assays.
In vitro choline kinase activity. The potential for PFOS to inhibit choline kinase enzyme activity was evaluated in recombinant human choline kinase alpha variant 1 (Abcam, accession number P35790, San Francisco, California), human choline kinase alpha variant 2 (OriGene Technologies, accession number NP_997634, Rockville, Maryland), and human choline kinase beta (R&D Systems, accession number Q9Y259, Minneapolis, Minnesota). Inhibition potential was measured using the NADH-coupled choline kinase assay (Trousil et al., 2013) . In brief, the choline kinase reaction was coupled to a pyruvate-NADH reaction as shown below and the production of NAD þ was calculated by measuring the depletion of NADH absorbance at 340 nm:
All reagents, pyruvate kinase (lyophilized powder), and lactate dehydrogenase (lyophilized powder) were obtained at the highest purity available from Sigma Aldrich. Triplicate wells received 400 mM PFOS in 10% DMSO, the highest soluble PFOS concentration, and choline concentrations from 2 to 1000 mM for a 15-min exposure (choline kinase alpha variant 1 and choline kinase beta) or a 40-min exposure (choline kinase alpha variant 2) that was in the linear region of NADH reduction for each enzyme. The absorbance at 340 nm was measured and the resulting data were converted to a velocity of NAD þ formation in pmole/ng protein/min. The concentration of PFOS in the dosing preparations was confirmed by LC/MS-MS using a previously described method (Zhao et al., 2015) . The results of 3 independent experiments for each enzyme were collated.
Statistical analyses. All statistical analyses were performed using GraphPad Prism, v. 6.04 (GraphPad Software, Inc., La Jolla, California). The in-life results were evaluated for statistical differences between groups within sex by one-way ANOVA with Tukey's multiple comparisons test. The potential for sexrelated differences in serum and liver choline and PFOS concentrations were evaluated by 2-way ANOVA with Bonferroni's multiple comparisons test. The measured choline and PFOS diet concentrations were compared with the target choline and PFOS diet concentrations by 1-sample t-tests. The PFOS concentration in the PFOS diet was compared with the PFOS concentration in the PFOS þ CS diet by 2-sample t-test.
RESULTS

Clinical Signs
No adverse clinical signs were observed in the control or CS groups of either sex of rats. Both male and female rats that were fed PFOS (6CS) were sensitive to light (ie, repeated squinting and vocalization) from day 17 to termination (3 to 5 of 12 in each sex). One female was hyper-reactive to touch on day 22, and one male had shaking, tremors, and running into the cage sides on day 23. All rats survived to scheduled necropsy. Minor abrasions/scabs were noted sporadically throughout the study across groups (data not provided). The observed sensitivity to light, hyper-reactivity, and seizures have been previously observed in rats at the same dietary PFOS dose after approximately 4 weeks of exposure in longer-term studies (Goldenthal et al., 1978a) .
Body Weights and Body Weight Gains
Male mean body weights were decreased in the PFOS þ CS group (5.1%-8.7%) relative to the control group from day 9 through termination ( Figure 1A ). Female mean body weights were decreased in the PFOS (6.2%-12.9%) and the PFOS þ CS (5.7%-11.9%) groups relative to the control group starting on days 9 and 11, respectively, through termination ( Figure 1B ). There were no other differences in mean body weights among the groups for either sex. The mean body weight gains of the male and female CS groups were similar to their respective control groups throughout the study (Figs. 1C and 1D ). Decreased mean body weight gains were noted in both the male and female PFOS and PFOS þ CS groups relative to the control groups across the study. For the males, the largest decreases relative to the control group were noted in week 1 (PFOS: 26%, PFOS þ CS: 38%) and week 3 (PFOS: 24%, PFOS þ CS: 47%). For the females, the largest decrease relative to the control group occurred in week 3 (PFOS: 80%, PFOS þ CS: 81%). There were no differences between the PFOS and PFOS þ CS groups for either sex at any timepoint.
Food Intake
There were no differences in mean daily food intake among the groups for male or female rats throughout the study (Figs. 1E  and 1F ).
Dietary Choline and PFOS Concentrations
The mean choline and PFOS concentrations were similar to the target concentrations for each diet with the exception of the PFOS diet which was significantly less than the target concentration (Supplementary Table 2 ). However, the PFOS concentrations in the PFOS and PFOS þ CS diets were similar to each Figure 1 . Effects of 3-week exposure to basal diet (control), CS diet, 100 ppm PFOS diet, or 100 ppm PFOS þ CS diet on male (A, C, and E) and female (B, D, and F) Sprague Dawley rat mean (6SD) body weights, body weight gains, and food intake, respectively (n ¼ 12 rats/sex/group). A, * PFOS þ CS male group was significantly different from the control group, p 0.05. B, PFOS (#) and PFOS þ CS (*) females were significantly decreased relative to the female control and CS groups, p . other. The coefficient of variation among the 6 samples for each diet was <13%, which indicated that the diets were homogenous (Supplementary Table 2 ). The diets had acceptable choline concentrations, PFOS concentrations, and homogeneity for use in the study.
Choline and PFOS Intake
Mean daily choline intake for the control, CS, PFOS, and PFOS þ CS groups, respectively, was approximately 107, 330, 102, and 307 mg/kg/d for male rats and 123, 375, 112, and 318 mg/kg/d for female rats (data not shown). Mean daily PFOS intake for both the PFOS and PFOS þ CS groups was approximately 6 mg/kg/d for male rats and 6.6 mg/kg/d for female rats. Mean daily PFOS intake for the control and CS groups was not calculated because the diets contained <0.05 ppm PFOS (Supplementary Table 2 ).
Serum Choline and PFOS Concentrations
Nonfasted male and female mean serum choline concentrations ranged from 4 to 9 ppm for all groups with the exception of the male CS group on day 9 ( Figs. 2A and 2B) . However, the male CS group day 9 mean was influenced by 4 rats with 14-16 ppm serum choline concentrations that may have been caused by food intake shortly prior to blood collection. The female groups had statistically significantly decreased mean serum choline concentrations relative to the male groups for all groups on day 9 and the CS groups on day 16; however, the magnitude of these differences was small and was not considered biologically relevant. On day 23, the mean serum choline concentration of the fasted male PFOS þ CS group was increased relative to all other male groups. Also on day 23, the mean serum choline concentration of the fasted female PFOS group was decreased relative to the control group. Sex-related differences were noted in the fasted female control and CS groups on day 23 where mean serum choline values were increased by 57% and 76%, respectively, relative to the male groups.
Mean serum PFOS concentrations of the control and CS groups were below the limit of quantitation (5 ppb). Mean serum PFOS concentrations in the PFOS and PFOS þ CS groups increased throughout the study with no differences between the groups at any timepoint (Figs. 2C and 2D ). Mean serum PFOS concentrations in female rats were higher than the respective male groups on days 9, 16, and 23 ( Figure 2D ).
Liver Choline and PFOS Concentrations
Mean choline concentrations were increased in the male PFOS and PFOS þ CS groups relative to the control group ( Figure 2E ). The male rats fed PFOS þ CS had decreased liver choline concentrations relative to the PFOS group, but the concentrations were not decreased to the control or CS group levels. The coefficient of variation for the male PFOS and PFOS þ CS group mean liver choline concentrations were high (57% and 68%, respectively). However, the mean values of the male PFOS and PFOS þ CS groups were much greater than the mean values for the male control and CS groups (10-and 5-fold, respectively). Although there is a high degree of variability in these data, the magnitude of the differences between the male groups suggests that these data are accurate and not an artifact of the methods. There were no differences in female liver choline concentrations among the 4 treatment groups.
All liver PFOS concentrations of the control and CS animals were below the limit of quantitation (0.05 ppm). Mean liver PFOS concentrations were similar between the PFOS and PFOS þ CS groups. There was no difference between sexes ( Figure 2F ).
Clinical Chemistry
Most clinical chemistry parameters were within the historical reference ranges for rats reported by Marshfield Labs (Marshfield Labs, 2016) . Selected clinical chemistry results are presented in Table 1 and the complete clinical chemistry results  are presented in Supplementary Tables 3-10 . Some incidental statistically significant differences were noted in liver (ie, aspartate aminotransferase, alanine transaminase, alkaline phosphatase, bilirubin (total, indirect and direct), gamma-glutamyl transferase), kidney (ie, blood urea nitrogen, creatinine, urea/ creatinine ratio, albumin, globulin, and albumin/globulin ratio), and pancreas clinical chemistry biomarkers (ie, amylase) of male and/or female rats across the evaluated timepoints, but these values were within the historical reference ranges and were not considered toxicologically relevant.
Mean serum total cholesterol, LDL, and HDL values were decreased on days 9, 16, and 23 in male rats that were fed the PFOS and PFOS þCS diets relative to the control and CS groups (Table 1 ). In addition, mean serum TG values were decreased on days 16 and 23 in male rats that were fed PFOS and PFOS þ CS relative to the control group (Table 1) . Male rats that were fed the CS diet had increased mean serum total cholesterol relative to the control group on days 9 and 16, but this effect was not observed in fasted rats on day 23. Mean serum total cholesterol and HDL values were decreased on days 9 and 16 in female rats that were fed the PFOS and PFOS þ CS diets relative to the control and/or CS groups. These effects were not noted in the fasted female rats on day 23. There were no differences in mean serum TG or LDL values for the female PFOS or PFOS þ CS groups relative to the control group at any timepoint. Lastly, there were no differences in serum cholesterol (total, HDL or LDL) or TGs values between the PFOS and PFOS þ CS groups of either sex at any timepoint.
Mean serum lactate dehydrogenase and lipase were consistently decreased for male and female rats that were fed PFOS and PFOS þ CS relative to the control and/or CS groups on days 2, 9, and 16 (Table 1) . On day 23, mean serum lactate dehydrogenase was increased in the male PFOS and PFOS þ CS groups relative to the CS group, but there was no difference relative to the control group. Also, on day 23, mean serum lipase was decreased in the male PFOS and PFOS þ CS groups relative to the control and CS groups. There were no significant differences in mean serum lactate dehydrogenase or lipase of the female PFOS and PFOS þ CS groups relative to the respective control and CS groups on day 23. The female CS group had decreased serum lactate dehydrogenase relative to the control group on day 23. The female control group had a very high standard deviation for the mean serum lactate dehydrogenase on day 23, which suggests the lack of a difference between the female control group and female PFOS and PFOS þ CS groups on day 23 may be a false negative result. Although increased serum lactate dehydrogenase and lipase are associated with pancreatic effects (Alhan et al., 2006; Frossard et al., 2008) , decreased serum lactate dehydrogenase and lipase have no toxicological relevance and therefore are not considered adverse. This conclusion is supported by the lack of differences in mean serum amylase values.
Terminal Fasted Body Weights and Absolute and Relative Liver Weights
There were no differences between the control and CS groups (both sexes) in mean fasted body weights, liver weights, or liverto-body weight ratios (Table 2 ). There were also no differences between the PFOS and PFOS þ CS groups (both sexes) for these parameters. Mean fasted body weights were decreased by 13%-14% in the PFOS (females only) and by 7%-14% in the PFOS þ CS group (both sexes) relative to the control group and CS group. Mean absolute liver weights were increased by 28%-33% in female rats that were fed PFOS or PFOS þ CS and by 65%-75% in male rats that were fed PFOS or PFOS þ CS relative to the control and CS groups. Similarly, mean liver-to-body weight ratios were increased in both the PFOS and PFOS þ CS groups (both sexes) relative to the control and CS groups. These liver weight Figure 2 . Effects of 3-week exposure to basal diet (control), CS diet, 100 ppm PFOS diet, or 100 ppm PFOS þ CS diet on male (A, C, E, and F) and female (B, D, E, and F) Sprague Dawley rat mean (6SD) serum choline, serum PFOS, liver choline, and liver PFOS concentrations, respectively (n ¼ 12 rats/sex/group). A, *CS group mean was increased relative all other group means, p .05. #PFOS þ CS group mean was increased relative all other group means, p .05. B, *PFOS group mean was decreased relative to the control group mean, p .05. a, All female group means were decreased relative to the respective male group means, p .05. b, Female CS group mean was decreased relative to the male CS group, p .05. c, Female control and CS group means were increased relative to the respective male groups, p .05. C and D, No significant differences between groups of the same sex, p > .05. #Female PFOS concentration was significantly increased relative to the male groups, p .05. Control and CS group values were below the limit of detection (0.05 ppm). E and F, Values with different letters are significantly different, p .05. increases are consistent with the known hepatomegaly effects of PFOS in rats (Curran et al., 2008; Elcombe et al., 2012a,b) , and the CS diet did not alter or reverse this PFOS effect.
Histopathology
Liver histology of male and female rats that were fed the CS diet was similar to the control diet (Supplementary Table 11 ). Liver histopathology findings were related to PFOS exposure and were not clearly influenced by choline supplement in the PFOS þ CS group (Supplementary Table 11 ). Representative Oil Red O-, osmium tetroxide-, and hematoxylin and eosin-stained liver sections from each group are presented in Figure 3 . Male rats that were fed the PFOS and PFOS þ CS diets had groundglass cytoplasmic alterations which are consistent with the known peroxisome proliferation effects of PFOS in rats (Curran et al., 2008; Elcombe et al., 2012a,b) . This ground-glass cytoplasm finding was not observed in female rats. A low incidence of minimal to moderate microscopic hepatic necrosis was noted in Globulin (g/dl) 2.8 6 0.2 2.9 6 0.1 2.8 6 0.1 2.8 6 0.1 2.5 6 0.1 2.6 6 0.1 2.6 6 0. male and female rats that were fed PFOS and PFOS þ CS. Hepatocellular hypertrophy was noted in the male and female PFOS and PFOS þ CS groups and was not present in the control or CS groups based on the microscopic evaluation (Supplementary Table 11 ) and morphometric data (Table 3) . A qualitative difference in hepatocellular hypertrophy incidence and severity was noted between the PFOS and PFOS þ CS groups (Supplementary Table 11 ); however, this difference was not supported by the morphometric evaluation of hypertrophy (Table  3 ). The hypertrophy morphometric evaluation was based on a large area that included normal hepatocytes as well as the centrilobular region where the hypertrophy occurred. Although measurements restricted to the centrilobular region may have improved the precision of the morphometric data, the data were considered acceptable based on the low standard deviations. Lipid content was increased in male rats that were fed PFOS and PFOS þ CS relative to the control and CS groups in both the Oil Red O-and osmium tetroxide-stained morphometric analyses (Table 3 ). There were no reproducible differences in lipid content between the female groups when the results of both the Oil Red O-and osmium tetroxide-staining were considered.
Liver FFA, Cholesterol, and TG Concentrations Mean hepatic FFA, cholesterol, and TG concentrations were similar between the control and CS groups for males and females (Figs. 4A-F ). There were no differences in hepatic cholesterol concentrations for any group. Mean hepatic FFA and TG concentrations were increased in male rats that were fed the PFOS and PFOS þ CS diets without regard to choline supplement status. However, mean hepatic FFA and TG concentrations were decreased in female rats that were fed the PFOS and PFOS þ CS diets again without regard to choline supplement status. Choline supplementation did not alter hepatic FFA or TG concentrations in male or female rats that were fed diets containing PFOS.
mRNA Analyses Ehhadh was upregulated 3.7-fold in male rats and 4.1-fold in female rats that were fed PFOS relative to the control groups (Supplementary Table 12 ). Scd1 was upregulated 9-fold in female rats that were fed PFOS relative to the control group. All other mRNA expression fold-changes in the PFOS groups were <2.5-fold and were not significantly different from the control groups.
In Vitro Nuclear Receptor Activation PFOS did not activate rat LXR-beta, human LXR-alpha, or rat PXR at concentrations up to 100 mM (Supplementary Table 13 ). PFOS was a mouse/rat PPAR-gamma agonist at the 100 mM concentration only. The rat CAR inverse agonist assay did not show any clear dose-related activation or inhibition of CAR. No cytotoxicity was observed at any concentration in any test. Creatinine ( In Vitro Choline Kinase Activity Analysis Based on a review of the Vmax and Km for all 3 forms of choline kinase, PFOS did not inhibit choline kinase in vitro ( Figure 5 ). The Vmax of the control-treated choline kinase alpha variant 2 used in this assay was 6-to 8-fold lower than the choline kinase alpha variant 1 and choline kinase beta forms.
DISCUSSION
Based on the results of this study, male rats that were fed 100 ppm PFOS in the diet for 3 weeks had hepatic steatosis that was not attenuated by increased dietary choline. Zhang et al. (2016) showed that 100 ppm PFOS in the diet could exacerbate the hepatic lipid accumulation caused by a minimal methionine-choline deficient diet in male mice and demonstrated the potential for a hepatic PFOS:choline-ion complex. Supplemental dietary choline prevented PFOS-induced hepatic lipid alterations in metabolism and hepatic oxidative stress in male mice at 30 ppm PFOS in the diet (Zhang et al., 2016) . However, in this study, a similar CS diet did not attenuate the PFOS-induced lipid accumulation in male rats when fed 100 ppm PFOS in the diet. The differences between these studies may indicate that at lower PFOS exposures there is an hepatic molar ratio of PFOS:choline that allows choline supplementation to decrease the hepatic steatotic effects that becomes overwhelmed at higher PFOS exposures. Some additional support for this hypothesis is the hepatic choline concentrations in this study.
The hepatic steatosis observed in male rats fed both PFOS diets occurred in the presence of increased hepatic choline concentrations. Male rats fed PFOS þ CS diet had decreased hepatic choline concentrations relative to the PFOS group, but it did not approach control or CS group levels and there were no differences in serum cholesterol or hepatic steatotic status. Female rats fed both PFOS diets did not have hepatic steatosis or increased hepatic choline concentrations. Taken together, these data suggest that there is a relationship between hepatic choline concentrations and the induction of hepatic steatosis caused by PFOS exposure. The PFOS-induced hepatic steatosis in this study was sexrelated with no evidence of hepatic steatosis occurring in female rats based on the hepatic FFA and TG concentrations as well as the Oil Red O and osmium tetroxide staining morphometric results. These findings occurred at similar hepatic PFOS concentrations in males and females, approximately 600 ppm, and were thus not related to hepatic PFOS concentration. Scd1 mRNA was upregulated in the female PFOS group; however, this would suggest greater FFA synthesis in the PFOS females relative to the control and there was no difference in Scd1 mRNA content between males and females that were fed the PFOS diet. Female primary rat hepatocytes have been shown to be more efficient than male hepatocytes at both oleate (Sorrentino et al., 1992) and palmitate (Luxon et al., 1998) influx. This would suggest that females should have higher hepatic lipid concentrations than males under PFOS exposure conditions. However, the increased efficiency of female hepatic cytosolic fatty acid binding protein (Sorrentino et al., 1992) may result in a greater mobilization of lipid to VLDL that would then be secreted to the blood and taken up by the adipose tissue. Fasted female rats of the control and CS groups had increased mean serum choline concentrations relative to the male rats in this study and in our previous work on choline dietary supplementation in rats (Bagley et al., 2017) , and may be evidence that females are mobilizing VLDL more efficiently than males. In addition, liver choline concentrations were not increased in female rats fed either PFOS-containing diet suggesting that female rats utilized the available choline, possibly through VLDL secretion, and maintained hepatic choline steady-state levels. Also, there were no differences in female serum LDL and TG concentrations of the PFOS groups relative to the control group in this study, which supports this proposed mechanism. Relative adiposity was not measured in this study, but it is a potential explanation for the mobilization of hepatic lipid in females and deserves further study. Albino rats prefer cages with lower light intensity (<100 lux) relative to cages with light intensities of 100-380 lux (Castelhano-Carlos and Baumans, 2009) . A minimum light intensity of 210 lux at working height has been recommended to improve performance of the animal care personnel (Schlingmann et al., 1993) . In this study, the light intensity within the hanging wire cages was approximately 0 lux; however, during handling the rats were exposed to light intensities of approximately 360-500 lux. This rapid change in light intensity while taking the rat from the cage into the room light may have contributed to the observations of light sensitivity in the PFOS and PFOS þ CS groups.
Activation of nuclear receptors (ie, CAR, PXR, LXR-alpha, LXR-beta, and PPAR-gamma) involved in lipid accumulation and upregulation of mRNA of enzymes involved in lipid accumulation (ie, Scd1, Cd36, and Fsp27) and oxidative stress response (ie, Gsst1) were investigated as potential mechanisms for the PFOS-induced hepatic steatosis. Although PFOS is a weak PPAR-gamma agonist at 100 mM in vitro, there were no other clear effects on nuclear receptors known to promote lipid accumulation. In addition, mRNA for Scd1, Cd36, Fsp27, and Gsst1 were not upregulated in male rats. Scd1 was upregulated 9-fold in female rats that were fed the PFOS diet relative to the control group; however, there was no lipid accumulation in female rats so the relevance of this finding is unclear. Ehhadh was upregulated in both sexes, which was expected given the role EHHADH protein plays in peroxisomal oxidation and previous findings in vitro where PFOS upregulated Ehhadh mRNA in primary rat hepatocytes (Bjork et al., 2011) . These findings suggest that PFOS-induced hepatic steatosis in male rats is not driven by activation of these nuclear receptors or through upregulation of mRNA involved in key hepatic steatosis pathways. Recent studies have indicated a PXR agonist potential for PFOS in vitro on human PXR (Zhang et al., 2017) and in vivo in mice (Bijland et al., 2011) and rats (Elcombe et al., 2012a,b) ; however, the luciferase data in the present study do not support the notion that PFOS directly activates rat PXR.
The potential for direct inhibition of choline kinase was investigated as a potential disruption of the first step in phosphatidylcholine synthesis. No effects were observed on the activity of human choline kinase alpha (variant 1 or 2) or human choline kinase beta. Rat choline kinases were not available for evaluation. However, the rat and human variants of these enzymes are >85% homologous, and the differences are not located in the ATP or choline binding sites, so it is unlikely that there would be any differences in outcome if the rat choline kinase enzymes had been evaluated. Based on the results in this study, PFOS does not directly inhibit choline kinase in vitro at relative PFOS:choline molar concentrations up to 200:1. Some cross-sectional epidemiology studies, where temporality cannot be determined, have reported modest associations in general populations between increased PFOS serum concentrations and increased serum concentrations of alanine aminotransferase (ALT) (Gallo et al., 2012; Lin et al., 2010), total cholesterol (Frisbee et al., 2010) , and nonHDL cholesterol (Nelson et al., 2010) . However, the magnitude of a potential effect on serum clinical chemistry is inconsistent across exposure levels when compared with the much more highly exposed PFOS production workers (Olsen et al., 2003 (Olsen et al., , 2012a . For example, analyzing 2 cycles of NHANES data (n ¼ 2216 adults), Lin et al. (2010) reported unadjusted ALT values increased from 23.8 to 27.7 U/l between the first and fourth quartiles of their PFOS concentrations (<15.5, >33 ng/ml). However, in an occupational study of 421 male PFOS production workers, Olsen et al. (2003) observed similarly increased ALT values (26-33 U/l) over a much greater quartile range of PFOS concentrations (mean values 270-2640 ng/ml). Furthermore, the rats fed 100 ppm PFOS for 23 days in this study had serum PFOS concentrations that were 7000-to 12 000-fold the worker serum PFOS concentrations reported by Olsen et al. (2012a) , where no association with ALT was reported in workers who were engaged in the demolition of perfluoroalkyl electrochemical fluorination cells. A 14-week dietary study in rats (Seacat et al., 2003a,b) fed 0.5, 2, 5, or 20 ppm PFOS showed hepatic vacuolation (ie, possible steatosis) in the 5 and 20 ppm groups at serum PFOS concentrations >600-fold the worker serum PFOS concentrations reported by Olsen et al. (2012a) . However, Seacat et al. (2003a,b) reported no hepatic vacuolation in rats at serum PFOS concentrations of 75-to 500-fold the worker serum concentrations reported by Olsen et al. (2012a) . Thus, it is unlikely that PFOS could induce hepatic steatosis in humans at the low exposures in workers and the general population.
In conclusion, dietary exposure of rats to 100 ppm PFOS for 3 weeks causes sex-related hepatic steatosis in males that is not attenuated by choline supplementation. These effects are not produced through nuclear receptor activation, upregulation of hepatic steatosis-promoting mRNA, or direct inhibition of choline kinase alpha-1, alpha-2, or beta which suggests that high exposure to PFOS is required to cause hepatic steatosis. The sex related differences in hepatic steatosis phenotype observed in this study should be further investigated.
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